IPNews® – The Federal Circuit on Friday affirmed the validity of Eli Lilly & Co.’s patent for its chemotherapy treatment Alimta, rejecting a challenge from generic drug makers Teva Parenteral Medicines Inc., Barr Laboratories Inc. and APP Pharmaceuticals Inc.
The three companies were seeking regulatory approval to market generic versions of Alimta, and contended that Eli Lilly’s patent was invalid or unenforceable. Alimta remains protected by patent through 2017, according to Eli Lilly. To continue reading, click: Eli Lilly Alimta Patent Validity Upheld On Appeal